Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase <scp>III</scp> trials

Paul, C.; Guenther, Lyn; Torii, Hideshi; Sofen, Howard; Burge, Russel; Lin, Chen-Yen; Bleakman, Alison Potts; Mallbris, Lotus; Poulin, Yves

doi:10.1111/jdv.14581

Cited by 21 publications

(7 citation statements)

References 19 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, an important proportion of patients reported skin lesions in highly impactful and difficult-to-treat areas such as the scalp (59%), nails (15%), palms and soles (9%), or sensitive areas such as the face (25%) and genitals (18%) -similar proportions compared to the worldwide literature. 15,16 These findings reinforce the extent of undertreatment in our population, since current guidelines recommend systemic therapy for patients with psoriasis affecting body areas where it is difficult to apply topical treatment such as the scalp, nails or palms and soles -leading to lower adherence to treatment and worse control of the diseaseand sensitive regions such as face and genitals due to the high impact of the disease in patient quality of life. 17 Regarding the treatment strategy, our population with psoriasis valued the complete resolution of skin lesions (64%), fastest onset of action (65%) and relief of pruritus (50%) the most.…”

Section: Discussionsupporting

confidence: 63%

Epidemiology of Psoriasis in Portugal: A Population-Based Study

Torres

Filipe

Brandão³

et al. 2023

Acta Med Port

View full text Add to dashboard Cite

Introduction: Psoriasis is a common, chronic, and inflammatory skin disorder with a high personal, social and economic burden and important implications for healthcare systems. The aim of this study was to provide an epidemiological characterization of individuals with psoriasis in Portugal.Material and Methods: A large observational, cross-sectional, nationwide, population-based survey study developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology (GPP-SPDV). A structured questionnaire was designed and applied by experienced interviewers to a random, representative sample of Portuguese individuals with psoriasis and/or psoriatic arthritis. Patients were considered to have psoriasis if they replied positively to one of the following questions: “Does any physician have ever diagnosed you with psoriasis?” or “Do you have a skin disorder characterized by scaling, reddish skin lesions located in the elbows/knees/scalp?”.Results: A total of 6381 individuals were interviewed, of which 283 met the criteria for psoriasis, corresponding to a prevalence rate of 4.4% (95% CI 3.95 – 4.98). Out of the participants that met psoriasis criteria, 24% had suggestive signs/symptoms but did not have a clinical diagnosis established and were not being monitored by a physician. Although more than 70% of participants had active disease (scaling, erythema, or pruritus) and one third had joint symptoms, only 12% were on systemic treatment. Fifty percent of participants with psoriasis (n = 139) had relevant comorbidities (most frequently depression/anxiety and cardiometabolic diseases). Sixteen percent of participants with psoriasis (n = 46) reported that psoriasis interfered with their daily activities (median impact of 5 in a 0 – 10 scale) and 12% mentioned the disease had an impact in their sexual life (median impact of 5 in a 0 – 10 scale).Conclusion: The results of this study suggest that the prevalence rate of psoriasis is likely to be high in Portugal, and several gaps exist at different levels of healthcare delivery to these patients, from diagnosis to treatment. This study provides important data for the future planning of interventions targeting the improvement of psoriasis care in Portugal.

show abstract

Section: Discussionsupporting

confidence: 63%

Epidemiology of Psoriasis in Portugal: A Population-Based Study

Torres

Filipe

Brandão³

et al. 2023

Acta Med Port

View full text Add to dashboard Cite

show abstract

“…Rapid improvements in skin and the ability to feel better quickly are important treatment attributes of a psoriasis therapy. These are important patient preferences for treatments and are ranked among the highest desired priorities in multiple reports [2,4,9,10,51,52]. However, rapid effect is also tied to longer-term outcomes, including skin improvement, quality of life, and reduction in itch [50,[53][54][55], though it must be noted that an association between rapid effect and long-term outcomes was not assessed in this analysis.…”

Section: Discussionmentioning

confidence: 99%

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses

Warren

See

Burge

et al. 2019

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Rapid improvement of psoriasis is valued by patients and should be considered to be an important factor in treatment selection. We investigated Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) response rates within the first 12 weeks of treatment to compare the rapid response of 11 biologic therapies for moderate-to-severe psoriasis using Bayesian and Frequentist network meta-analyses (NMA). Methods: A systematic literature review was conducted to identify phase 3, double-blind, randomized, controlled trials for adult patients with moderate-to-severe psoriasis treated with interleukin (IL)-17 (brodalumab, ixekizumab, secukinumab), IL-12/-23 (ustekinumab), IL-23 (guselkumab, risankizumab, tildrakizumab), or tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab). Outcome measures extracted from 32 publications were C 75, C 90, or 100% improvement in PASI score (PASI 75, PASI 90, or PASI 100, respectively) at weeks 2, 4, 8, and 12 and DLQI (0,1), where score (0,1) indicates no effect on patient's life, at week 12. Bayesian NMA (BNMA) used fixed-treatment effect and random-baseline effect, normal independent models. Frequentist NMA (fNMA) was conducted as sensitivity analyses to test the robustness of the findings. Results: Based on BNMA and fNMA, brodalumab and ixekizumab showed the most rapid treatment effects on PASI 75 at weeks 2, 4, and 8 and on PASI 90 and PASI 100 at weeks 2, 4, 8, and 12; ixekizumab overlapped with risankizumab on PASI 75 at week 12. Brodalumab, ixekizumab, and secukinumab yielded higher DLQI (0,1) gains at week 12 compared to all of the other biologics studied. Additional measures of quality of life were not assessed in this report. Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.9994610.

show abstract

“…A recent study evaluating more than 1100 patients with facial psoriasis showed that ixekizumab, an interleukin 17A antagonist, is an effective treatment alternative to traditional therapies. 10 Adalimumab is also efficacious in the treatment of facial psoriasis, with superior responses when compared to methotrexate or placebo. 3 The selection of adalimumab as biologic therapy was based on the patient's insurance coverage in this case.…”

Section: Discussionmentioning

confidence: 99%